Seroprevalence of pre-existing NABs against AAV1, 2, 5, 6 and 8 in the South African Hemophilia B patient population

Anna Majowicz1, Nolukholo Ncete2, Floris van Waes1, Sander J. van Deventer1 Johnny N. Mahlangu1 and Valerie Ferreira1
1uniQure N.V., Amsterdam, The Netherlands. 2Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, Faculty of Health Sciences and NHLS, T York Road, Parktown, 2193 Johannesburg, South Africa

Background
The impact of pre-existing anti-AAV neutralizing antibodies (NABs) on liver transduction following systemic administration of AAV-based gene therapy varies between AAV serotypes. Titters of anti-AAV2 or anti-AAV8 NABs as low as 5 have been related to a decrease or even total impairment of AAV liver transduction after systemic delivery in humans [1, 2]. However, successful gene transfer has been reported in patients with anti-AAV NAB titers up to 340 and in non-human primates with titers up to 1030 [3]. A significant proportion of individuals develop humoral immunity against various AAV serotypes already early in life, starting around 2 years of age. Furthermore, the prevalence of antibodies to different AAV vector serotypes has been reported to vary according to geographical location [4, 5]. Therefore, it is of interest to determine the prevalence of NABs against different AAV serotypes in population to be potentially treated with AAV-based gene therapy.

Study Objective
Establishing anti-AAV NABs seroprevalence in South African hemophilia B patient population (n=44) using a panel of AAV serotypes suitable for liver-targeted therapy. Results will determine the AAV serotypes likely to be of greatest clinical applicability for gene therapy in the South African Hemophilia B population.

Methods
Hemophilia B patient (n=44) and healthy donors (n=44) serum samples were obtained from Hemophilia Comprehensive Care Center in Johannesburg (South Africa). All the serum samples were analyzed for the presence of NABs against AAV serotypes 1, 2, 5, 6 and 8 with the use of a highly sensitive luciferase-based bioassays (Figure 1).

Results
Anti-AAV5 and anti-AAV8 NABs are the least prevalent in both South African Hemophilia B patients and healthy donor population
• The presence of NABs against the AAV serotypes 1, 2, 5, 6 and 8 was found in the serum of the hemophilia B patients (Figure 2). The highest prevalence of NABs was found to be against the AAV2 serotype, 95% (n=42/44), followed by the AAV1 and AAV6 serotypes, both of which was 77% (n=34/44). The prevalence of NABs against AAV5 and AAV8 was the lowest, 64% (n=28/44) for both serotypes. Similar pattern was also observed in healthy donor population from South Africa (Figure 2).
• Serum samples positive for anti-AAV2 NABs had a highest occurrence of titers above 1030 (39%) in comparison to anti-AAV1 NABs (20%), anti-AAV5 NABs (5%) or anti-AAV6 NABs (7%). The occurrence of samples with low titers (ranging from titer of 9 to titer of 50) was the highest for anti-AAV8 NABs (32%) and for anti-AAV2 NABs (20%), followed by anti-AAV1 (18%) and anti-AAV5 (6%) (Figure 2).

Figure 1. General principle of functional anti-AAV NABs detection.
Anti-AAV NABs titters were determined by calculation of the percentage of neutralization for each sample dilution and fitting the neutralization curve with a four-parameter method. Anti-AAV NABs titter (IC50) is the dilution at which antibodies inhibit HeLa293T cell transduction with AAV-LUC by 50%. The lowest patient serum dilution used in every assay was 8. All analytical runs included proper negative and positive controls.

Figure 2. Prevalence and distribution of titers of pre-existing NABs against different AAV serotypes in South African hemophilia B patients and healthy donor population. Total number of analyzed patient or healthy donor serum samples was 44 per group. NAB, neutralizing antibody; AAV, adeno-associated virus.

Figure 3. Individual anti-AAV NABs titers measured in serum of South African Hemophilia B patients and healthy donors. Mean SSD titer is depicted in red. Total number of analyzed patient or healthy donor serum samples was 44 per group. NAB, neutralizing antibody; AAV, adeno-associated virus; SD, standard deviation.

Figure 4 Theoretical eligibility of South African hemophilia B patients for systemic AAV1, 2, 5, 6 and 8- based gene therapy. Total number of analyzed patient serum samples was 44. NAB, neutralizing antibody; AAV, adeno-associated virus.

Conclusion
Seroprevalence of pre-existing anti-AAV NABs among South African hemophilia B patients and healthy controls is considerably lower for AAV5 and AAV8 than for AAV1 and 2. The results of our anti-AAV NABs seroprevalence study in South African hemophilia B patient population show that at least 95% of those patients could benefit from treatment with AAV5 vector-based gene therapy, while 23%, 5% 18%, 36% of the patients tested would be included in trials using systemic delivery of AAV1, AAV2, AAV6, or AAV8 vectors.

 References

Disclosure
Declarations of Interest: None for the authors.}

Poster No. 3353